Quillivant XR (Methylphenidate HCl) Patent Expiration, LOE Window & CMS Spending
Quillivant XR (Methylphenidate HCl) by Nextwave A Sub Of Tris: FDA Orange Book LOE 2031-02-15, 1 AB generics, $98.8M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Nextwave A Sub Of Tris |
| FDA Application & Pathway | N202100 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2031-02-15 |
| Orange Book Patents (*PED Extensions) | 7 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 1 |
| 2024 CMS Total Public Spend | $98.8M |
| 2024 Medicare Part D Spend | $188K |
| 2024 Medicaid Spend | $98.6M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |